Gregory Crane

495 total citations
11 papers, 200 citations indexed

About

Gregory Crane is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gregory Crane has authored 11 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Cancer Research and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gregory Crane's work include Breast Cancer Treatment Studies (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (4 papers). Gregory Crane is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (4 papers). Gregory Crane collaborates with scholars based in United States, Australia and Belgium. Gregory Crane's co-authors include Anne O’Dea, Priyanka Sharma, Qamar J. Khan, Jamie L. Wagner, Lauren Nye, Andrew K. Godwin, Rachel Yoder, Milind A. Phadnis, Joshua M. Staley and Kelsey Schwensen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Gregory Crane

9 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory Crane United States 6 162 90 70 38 18 11 200
Marion Pedrero France 3 135 0.8× 68 0.8× 70 1.0× 65 1.7× 51 2.8× 3 193
Jean Mourlanette France 4 263 1.6× 164 1.8× 174 2.5× 51 1.3× 37 2.1× 4 312
Zhao-Li Tan China 7 127 0.8× 69 0.8× 42 0.6× 23 0.6× 61 3.4× 17 186
Avi Spira United States 3 121 0.7× 59 0.7× 63 0.9× 76 2.0× 72 4.0× 7 202
Nicolas Brandone France 5 177 1.1× 43 0.5× 155 2.2× 35 0.9× 59 3.3× 8 249
Barbara Ingold Heppner Germany 6 208 1.3× 48 0.5× 76 1.1× 42 1.1× 20 1.1× 6 229
Tressa Hood United States 8 71 0.4× 43 0.5× 32 0.5× 25 0.7× 37 2.1× 20 133
A. Swat Switzerland 4 305 1.9× 112 1.2× 135 1.9× 89 2.3× 45 2.5× 6 354
Kelsey Schwensen United States 4 114 0.7× 62 0.7× 35 0.5× 36 0.9× 20 1.1× 6 150
Amy Hankin United States 7 161 1.0× 41 0.5× 78 1.1× 58 1.5× 77 4.3× 28 210

Countries citing papers authored by Gregory Crane

Since Specialization
Citations

This map shows the geographic impact of Gregory Crane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Crane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Crane more than expected).

Fields of papers citing papers by Gregory Crane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Crane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Crane. The network helps show where Gregory Crane may publish in the future.

Co-authorship network of co-authors of Gregory Crane

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Crane. A scholar is included among the top collaborators of Gregory Crane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Crane. Gregory Crane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Stecklein, Shane R., Roberto Salgado, Julia White, et al.. (2025). Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 124(3). 717–725.
2.
3.
4.
Stecklein, Shane R., Rachel Yoder, Roberto Salgado, et al.. (2023). Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy. Cancer Research. 83(5_Supplement). PD1–6. 2 indexed citations
5.
Stecklein, Shane R., Rachel Yoder, Joshua M. Staley, et al.. (2023). Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.. Journal of Clinical Oncology. 41(16_suppl). 507–507. 4 indexed citations
6.
Khan, Qamar J., Milind A. Phadnis, Manana Elia, et al.. (2023). Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.. Journal of Clinical Oncology. 41(16_suppl). 1007–1007. 7 indexed citations
7.
Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2023). Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology. 10(2). 227–227. 78 indexed citations
8.
Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2022). Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).. Journal of Clinical Oncology. 40(16_suppl). 513–513. 37 indexed citations
9.
Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2021). Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). 1076–1076. 16 indexed citations
10.
Khan, Qamar J., Anne O’Dea, Aditya Bardia, et al.. (2020). Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).. Journal of Clinical Oncology. 38(15_suppl). 505–505. 47 indexed citations
11.
Sharma, Priyanka, Bruce F. Kimler, Anne O’Dea, et al.. (2019). Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).. Journal of Clinical Oncology. 37(15_suppl). 516–516. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marion Pedrero Breakdown of academic impact, for papers by Jean Mourlanette Breakdown of academic impact, for papers by Zhao-Li Tan Breakdown of academic impact, for papers by Avi Spira Breakdown of academic impact, for papers by Nicolas Brandone Breakdown of academic impact, for papers by Barbara Ingold Heppner Breakdown of academic impact, for papers by Tressa Hood Breakdown of academic impact, for papers by A. Swat Breakdown of academic impact, for papers by Kelsey Schwensen Breakdown of academic impact, for papers by Amy Hankin
Rankless by CCL
2026